ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
ReShape Lifesciences (Nasdaq: RSLS) has secured a significant Australian patent for its Diabetes Neuromodulation technology, valid until April 2039. The technology utilizes the company's proprietary vBloc™ platform to treat Type 2 diabetes through vagus nerve modulation.
The system employs targeted bioelectronic modulation of vagal nerves using implanted electrodes and an intelligent pulse generator that interfaces with external devices and glucose monitors. Preclinical studies in Zucker rats and alloxan-treated swine have demonstrated effective glycemic control. The technology is supported by 63 issued or pending patents covering areas including vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.
ReShape Lifesciences (Nasdaq: RSLS) ha ottenuto un importante brevetto australiano per la sua tecnologia di neuromodulazione per il diabete, valido fino ad aprile 2039. La tecnologia sfrutta la piattaforma proprietaria vBloc™ dell'azienda per trattare il diabete di tipo 2 mediante la modulazione del nervo vago.
Il sistema utilizza una modulazione bioelettronica mirata dei nervi vagali tramite elettrodi impiantati e un generatore di impulsi intelligente che si interfaccia con dispositivi esterni e monitor del glucosio. Studi preclinici su ratti Zucker e suini trattati con allossano hanno dimostrato un controllo glicemico efficace. La tecnologia è supportata da 63 brevetti concessi o in attesa che coprono ambiti quali la neuromodulazione vagale, la regolazione del glucosio, l'intelligenza artificiale e applicazioni abilitate al Bluetooth.
ReShape Lifesciences (Nasdaq: RSLS) ha obtenido una patente significativa en Australia para su tecnología de neuromodulación para la diabetes, válida hasta abril de 2039. La tecnología utiliza la plataforma propietaria vBloc™ de la compañía para tratar la diabetes tipo 2 mediante la modulación del nervio vago.
El sistema emplea una modulación bioelectrónica dirigida de los nervios vagales utilizando electrodos implantados y un generador de pulsos inteligente que se conecta con dispositivos externos y monitores de glucosa. Estudios preclínicos en ratas Zucker y cerdos tratados con aloxano han demostrado un control glucémico efectivo. La tecnología está respaldada por 63 patentes otorgadas o en trámite que abarcan áreas como la neuromodulación vagal, regulación de glucosa, inteligencia artificial y aplicaciones habilitadas con Bluetooth.
ReShape Lifesciences (나스닥: RSLS)는 2039년 4월까지 유효한 당뇨병 신경조절 기술에 대한 중요한 호주 특허를 획득했습니다. 이 기술은 회사의 독자적인 vBloc™ 플랫폼을 활용하여 제2형 당뇨병을 미주신경 조절을 통해 치료합니다.
이 시스템은 이식된 전극과 외부 장치 및 혈당 모니터와 연동되는 지능형 펄스 생성기를 사용하여 표적 생체 전자 조절을 미주신경에 적용합니다. 주커(Zucker) 쥐와 알록산 처리 돼지를 대상으로 한 전임상 연구에서 효과적인 혈당 조절이 입증되었습니다. 이 기술은 미주신경 신경조절, 혈당 조절, 인공지능, 블루투스 지원 애플리케이션 등 다양한 분야를 포함하는 63건의 등록 또는 출원 중인 특허로 뒷받침되고 있습니다.
ReShape Lifesciences (Nasdaq : RSLS) a obtenu un brevet australien important pour sa technologie de neuromodulation du diabète, valable jusqu'en avril 2039. Cette technologie utilise la plateforme propriétaire vBloc™ de la société pour traiter le diabète de type 2 par modulation du nerf vague.
Le système emploie une modulation bioélectronique ciblée des nerfs vagues à l'aide d'électrodes implantées et d'un générateur d'impulsions intelligent qui s'interface avec des dispositifs externes et des moniteurs de glucose. Des études précliniques sur des rats Zucker et des porcs traités à l'alloxane ont démontré un contrôle glycémique efficace. La technologie est soutenue par 63 brevets délivrés ou en attente couvrant des domaines tels que la neuromodulation vagale, la régulation du glucose, l'intelligence artificielle et les applications compatibles Bluetooth.
ReShape Lifesciences (Nasdaq: RSLS) hat ein bedeutendes australisches Patent für seine Diabetes-Neuromodulationstechnologie erhalten, das bis April 2039 gültig ist. Die Technologie nutzt die firmeneigene vBloc™-Plattform zur Behandlung von Typ-2-Diabetes durch Modulation des Vagusnervs.
Das System verwendet eine gezielte bioelektronische Modulation der Vagusnerven mittels implantierter Elektroden und eines intelligenten Impulsgenerators, der mit externen Geräten und Glukosemonitoren kommuniziert. Präklinische Studien an Zucker-Ratten und Alloxan-behandelten Schweinen zeigten eine effektive Blutzuckerkontrolle. Die Technologie wird durch 63 erteilte oder anhängige Patente unterstützt, die Bereiche wie vagale Neuromodulation, Glukoseregulierung, künstliche Intelligenz und Bluetooth-fähige Anwendungen abdecken.
- Patent protection secured until April 2039 in Australia
- Technology demonstrated effective glycemic control in preclinical studies
- Strong intellectual property portfolio with 63 issued or pending patents
- Potential to reduce patient dependence on daily diabetes medications
- Technology still in preclinical stage, not yet proven in human trials
- Commercialization timeline and regulatory approval path not specified
Insights
ReShape's new Australian patent for diabetes neuromodulation technology strengthens their IP portfolio and expands their global market opportunities through 2039.
This patent grant represents a significant expansion of ReShape Lifesciences' intellectual property portfolio in the diabetes treatment space. The Australian patent (number 2019252920) provides protection until April 12, 2039, giving the company nearly 15 years of market exclusivity for their vagus nerve neuromodulation technology in this territory.
The technology combines both vagus nerve block (vBloc™) and stimulation approaches to address Type 2 diabetes, which affects millions globally and remains challenging to treat effectively. What makes this system particularly innovative is its ability to deliver dynamically responsive therapy based on real-time glucose levels through an intelligent pulse generator that communicates with external monitoring devices.
The preclinical validation in Zucker rats and alloxan-treated swine models demonstrates early proof-of-concept for glycemic control, though it's important to note this technology appears to be in pre-clinical stages and hasn't yet entered human trials. This patent is part of a broader IP strategy, with the company reporting 63 issued or pending patents covering vagal neuromodulation, glucose regulation, AI, and Bluetooth applications.
From a competitive standpoint, this patent strengthens ReShape's position in the neuromodulation space for metabolic disorders. The technology potentially offers advantages over conventional diabetes treatments by reducing medication dependence and providing more consistent glucose control, which could translate to improved outcomes and potentially lower healthcare costs if successfully commercialized.
Vagal Neuromodulation Offers a Novel Approach to Treating Type 2 Diabetes and Hypoglycemia
IRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was granted a key international patent from the Australian Patent Office for its Diabetes Neuromodulation technology. Patent number 2019252920, entitled, “Simultaneous Multi-Site Vagus Nerve Neuromodulation For Improved Glycemic Control System And Methods,” will provide protection until April 12, 2039. The Diabetes Neuromodulation system leverages its proprietary vagus nerve block (vBloc™) technology platform, along with vagus nerve stimulation, to treat Type 2 diabetes, a prominent disorder linked with obesity.
“Type 2 diabetes remains a global health challenge and continues to be difficult to treat effectively, despite numerous pharmacological and surgical interventions, “stated Jonathan Waataja, Ph.D., Director of Research at ReShape Lifesciences®. “Our Diabetes Neuromodulation system, now protected under a newly granted Australian patent, offers a novel approach by using targeted bioelectronic modulation of vagal and related nerves to manage glucose regulation. The system delivers precisely programmed electrical signals—either to stimulate or block neural activity—through implanted electrodes and an intelligent pulse generator that communicates with an external device and glucose monitor. This design not only enables dynamic, responsive therapy based on real-time glucose levels but also does so with energy-efficient, intermittent signal bursts. Preclinical studies in Zucker rats and alloxan-treated swine models have shown effective glycemic control using this system, reinforcing the therapeutic potential of this personalized neuromodulation approach for managing type 2 diabetes and hypoglycemia.”
“The granting of this Australian patent is a major milestone that strengthens our international intellectual property position and highlights the global relevance of our Diabetes Neuromodulation technology,” stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences. “This innovation is designed to personalize diabetes treatment by tailoring therapy to each patient’s needs, using targeted nerve signals to help regulate blood sugar levels more effectively. It has shown strong promise to potentially reduce dependence on daily medications, improving consistency in glucose control, and ultimately lowering the overall cost and burden of managing diabetes—both for patients and the healthcare system. Similar to other patent families within ReShape, the Diabetes Neuromodulation technology is backed by a strong intellectual property portfolio, consisting of 63 issued or pending patents. These patents span key areas such as vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications—collectively securing a clear path to potential commercialization and offering robust protection against competitive threats.”
About The ReShape Diabetes Neuromodulation Device
The ReShape Diabetes Neuromodulation system (formerly, Diabetes Bloc-Stim Neuromodulation™ (DBSN™) is a novel minimally invasive therapeutic implant concept that delivers bio-electronic neuromodulation of vagus nerve branches that are innervating organs which regulate plasma glucose. The system stimulates vagus celiac fibers of the pancreas to release insulin during stimulation, while blocking the hepatic vagal branch, innervating the liver, to decrease glucose release and decrease insulin resistance following ligation. The system utilizes a proprietary, reversable and adjustable electrical blockade that may represent the future of personalized medicine. Reshape Lifesciences believes its system is superior to both standalone stimulation of the vagus nerve, and vagus nerve ligation which has undesirable side effects and causes irreversible damage to the nerve.
About ReShape Lifesciences®
ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® and Lap-Band® 2.0 Flex Systems provide minimally invasive, long-term treatment of obesity and are an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit www.reshapelifesciences.com.
As previously announced ReShape has entered into an asset purchase agreement with Biorad Medisys, Pvt. Ltd., pursuant to which ReShape has agreed to sell substantially all of its assets to Biorad (or an affiliate thereof), including ReShape’s Lap-Band® System, Obalon® Gastric Balloon System and the DBSN™ system (but excluding cash). Therefore, at the closing of the transactions contemplated by the asset purchase agreement, the DBSN™ system will be owned by Biorad.
Forward-Looking Safe Harbor Statement
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those discussed due to known and unknown risks, uncertainties, and other factors. These forward-looking statements generally can be identified by the use of words such as "expect," "plan," "anticipate," "could," "may," "intend," "will," "continue," "future," other words of similar meaning and the use of future dates. Forward-looking statements in this press release include statements about the promise of the Diabetes Neuromodulation technology and the potential path to commercialization of the technology. These and additional risks and uncertainties are described more fully in the company's filings with the Securities and Exchange Commission, including those factors identified as "risk factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
CONTACTS
ReShape Lifesciences Investor Contact:
Paul F. Hickey
President and Chief Executive Officer
949-276-7223
ir@ReShapeLifesci.com
Investor Relations Contact:
Rx Communications Group
Michael Miller
917-633-6086
mmiller@rxir.com
FAQ
What is the new Australian patent granted to ReShape Lifesciences (RSLS)?
How does ReShape Lifesciences' (RSLS) Diabetes Neuromodulation system work?
What are the potential benefits of RSLS's Diabetes Neuromodulation technology?
What clinical evidence supports ReShape Lifesciences' (RSLS) diabetes technology?
How strong is RSLS's intellectual property portfolio for diabetes technology?
